KR20090033375A - Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포 - Google Patents

Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포 Download PDF

Info

Publication number
KR20090033375A
KR20090033375A KR1020097002075A KR20097002075A KR20090033375A KR 20090033375 A KR20090033375 A KR 20090033375A KR 1020097002075 A KR1020097002075 A KR 1020097002075A KR 20097002075 A KR20097002075 A KR 20097002075A KR 20090033375 A KR20090033375 A KR 20090033375A
Authority
KR
South Korea
Prior art keywords
cells
carcinoma
cancer
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097002075A
Other languages
English (en)
Korean (ko)
Inventor
안나 캐롤리나 팔루카
자끄 에프. 방쉐로
니콜라스 타키에
수잔 버크홀더
Original Assignee
베일러 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베일러 리서치 인스티튜트 filed Critical 베일러 리서치 인스티튜트
Publication of KR20090033375A publication Critical patent/KR20090033375A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020097002075A 2006-06-30 2007-06-29 Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포 Abandoned KR20090033375A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30

Publications (1)

Publication Number Publication Date
KR20090033375A true KR20090033375A (ko) 2009-04-02

Family

ID=38895372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002075A Abandoned KR20090033375A (ko) 2006-06-30 2007-06-29 Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포

Country Status (8)

Country Link
US (1) US20080031900A1 (https=)
EP (2) EP2630968A1 (https=)
JP (3) JP2009542714A (https=)
KR (1) KR20090033375A (https=)
CN (1) CN101511384A (https=)
AU (1) AU2007269245B2 (https=)
CA (1) CA2691346A1 (https=)
WO (1) WO2008005859A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0915582A2 (pt) * 2008-06-06 2016-01-26 Baylor Res Inst anticorpos anto-cd8 que bloqueiam a sensibilização de efetores citotóxicos e levam à geração de células t cd8+ reguladoras
WO2009155332A1 (en) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
CA2843200A1 (en) * 2011-07-27 2013-01-31 Baylor Research Institute Dendritic cell (dc)-vaccine therapy for pancreatic cancer
AU2012325758A1 (en) * 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon
EP2591798B1 (en) 2011-11-09 2014-11-19 Werner Lubitz Vaccine for use in tumor immunotherapy
US9962433B2 (en) 2012-12-28 2018-05-08 Amphera B.V. Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2016148179A1 (ja) * 2015-03-17 2016-09-22 国立大学法人信州大学 Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
EP3397263B1 (en) * 2015-12-30 2023-09-20 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
CA3087418A1 (en) * 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
JP2022522802A (ja) * 2019-03-01 2022-04-20 グリットストーン バイオ， インコーポレイテッド Ｔ細胞受容体の選択
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JP2023013211A (ja) * 2021-07-15 2023-01-26 大日本印刷株式会社 細胞医薬品の提供方法、細胞医薬品用ラベルの作成方法、情報処理方法、プログラム、細胞医薬品、細胞医薬品容器および細胞医薬品提供システム
WO2024112647A1 (en) 2022-11-23 2024-05-30 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
JP2002509114A (ja) * 1998-01-16 2002-03-26 バイオミラ・ユーエスエイ・インコーポレイテッド 膜プロテオリポソームから作製される患者特異的白血球悪性腫瘍ワクチン
EP1056834A2 (en) * 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
ATE552011T1 (de) * 2003-10-15 2012-04-15 Ist Superiore Sanita Kolorektal-karzinom-antigen
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞

Also Published As

Publication number Publication date
WO2008005859A2 (en) 2008-01-10
CA2691346A1 (en) 2008-01-10
EP2630968A1 (en) 2013-08-28
JP2013177430A (ja) 2013-09-09
JP2016041725A (ja) 2016-03-31
EP2037957A4 (en) 2010-09-08
EP2037957A2 (en) 2009-03-25
US20080031900A1 (en) 2008-02-07
CN101511384A (zh) 2009-08-19
AU2007269245B2 (en) 2012-04-12
AU2007269245A1 (en) 2008-01-10
WO2008005859A3 (en) 2008-11-20
JP6134763B2 (ja) 2017-05-24
JP2009542714A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
KR20090033375A (ko) Ｇｍ-ｃｓｆ 및 인터페론 알파의 사용에 의해 생성되고 열처리 및 사멸된 암 세포가 로딩된 수지상 세포
Strome et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response
Schuler et al. The use of dendritic cells in cancer immunotherapy
RU2575978C2 (ru) Система и способ получения и хранения активированных зрелых дендритных клеток
Reardon et al. The development of dendritic cell vaccine-based immunotherapies for glioblastoma
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
JP5709264B2 (ja) ワクチン組成物および方法
US20080112924A1 (en) Dendritic Cells Loaded with Heat Shocked Melanoma Cell Bodies
CA2228176A1 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
JP2013507986A (ja) 抗原特異的ｔ細胞の増殖のための方法
JP2014521657A (ja) 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法
JP4841794B2 (ja) ヒト樹状細胞による外因性抗原のクラスｉ提示を増加させる方法
US20190046568A1 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
EP1959007A1 (en) Method for providing mature dendritic cells
CA2555984A1 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
Waeckerle‐Men et al. Dendritic cells generated from patients with androgen‐independent prostate cancer are not impaired in migration and T‐cell stimulation
Wan et al. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA
HK40010200A (en) Induction of il-12 using immunotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131218

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141027

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee